Thrivent Financial for Lutherans

Position in PTGX — Protagonist Therapeutics, Inc

CIK 314984 Minneapolis, MN

Position in PTGX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$4,866,058

+$731,743 QoQ

Shares Held

39,697

+1.2% QoQ

Ownership

0.061%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#103

of 341 holders

Holding Since

Sep 2022

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Thrivent Financial for Lutherans holds $349,109,213 across 50 Biotechnology names. PTGX ranks #14 (1.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	EXEL	Exelixis, Inc.	1,620,743	$88,184,625
2	REGN	Regeneron Pharmaceuticals, Inc.	131,457	$81,968,697
3	RPRX	Royalty Pharma plc	740,772	$41,535,085
4	JAZZ	Jazz Pharmaceuticals plc	80,500	$19,398,084
5	ARGX	Argenx SE	12,688	$11,771,545
6	VRTX	Vertex Pharmaceuticals Inc / Ma	20,169	$10,018,546
7	VCEL	Vericel Corp	170,272	$7,575,400
8	KRYS	Krystal Biotech, Inc.	17,229	$6,403,502

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$4,866,058	39,697	+1.2%	Shares	Sole	2026-08-14
2026-03-31	$4,134,315	39,225	-2.9%	Shares	Sole	2026-05-01
2025-12-31	$3,526,789	40,380	-4.3%	Shares	Sole	2026-02-05
2025-09-30	$2,802,548	42,188	-7.4%	Shares	Sole	2025-11-04
2025-06-30	$2,518,985	45,576	+4.1%	Shares	Sole	2025-08-26
2025-03-31	$2,117,007	43,776	-5.0%	Shares	Sole	2025-08-26
2024-12-31	$1,778,147	46,066	-0.4%	Shares	Sole	2025-02-10
2024-09-30	$2,081,565	46,257	-37.0%	Shares	Sole	2024-11-07
2023-06-30	$2,026,782	73,381	-27.3%	Shares	Defined	2023-08-14
2023-03-31	$2,322,839	100,993	0.0%	Shares	Sole	2023-05-17
2022-12-31	$1,101,832	100,993	0.0%	Shares	Sole	2023-02-08
2022-09-30	$851,370	100,993	—	Shares	Defined	2022-11-14
No filing history on record for this holder in this stock.